"The voice for cancer physicians and their patients in Massachusetts."

  • Home
  • Resources
  • FDA Approvals
  • FDA APPROVED IBRUTINIB (IMBRUVICA) FOR THE TREATMENT OF ADULT PATIENTS WITH CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD)

FDA APPROVED IBRUTINIB (IMBRUVICA) FOR THE TREATMENT OF ADULT PATIENTS WITH CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD)

07 Aug 2017 10:11 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration approved ibrutinib (Imbruvica, Pharmacyclics) for the treatment of adult patients with chronic graft versus host disease (cGVHD) after failure of one or more lines of systematic therapy. Read full press release.

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software